SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David Cathcart who wrote (1122)10/16/1998 1:09:00 PM
From: lrb  Read Replies (1) of 1826
 
I listened to the CC yesterday, and felt better about MOGN's situation
than I did after reading the earnings release. My concern was that
Salagen sales were not growing; that the Sjogren's indication was not
panning out as we had hoped. Blitzer was very upbeat on Salagen's
progress in the call. Revenue from Salagen increased only 6% over the
preceding quarter. But they said that the data that tracks sales
of Salagen by wholesalers to pharmacies (DDD Data?), which tends to
be less volatile than MGI's direct sales, continued to show growth
near the high end of its historical range, which they said was between
6% and 40%. These numbers are from memory, someone can correct me
if I've misquoted. They said that the sales force still had lots of
physicians in the appropriate specialty to contact; they believe
continued growth is sustainable.

The head of research, in response to questions about the significance
of the PI tumor shrinkage, said that while no one would consider
predicting FDA approval based on the outcome of a single patient, he
believed that it is probable that MGI-114 will find a place in the
market. I hope someone who took notes during the call will be able
to relate more precisely what he said during this exchange, because
I want to ask thread experts about it. For those of you with
real knowledge of the science and the industry, can you comment on
the significance of a single patient in a PI trial experiencing
a partial response in treatment for pancreatic cancer, and another
patient exhibiting a minor response (< 50% shrinkage) in treatment for
cancer of the thymus?

They continued their stonewalling on the Euro partner issue. A
deal will be made sometime in the future when a certain set of
things happen, without any elaboration on what those things are or
when they might happen. I am less frustrated by this position than I
was three months ago, because MGI appears less vulnerable than it did
then, what with good growth in Salagen sales and positive cash flow.
I suspect Blitzer is unwilling to commit to a schedule lest it be
used by a potential partner to get concessions that he doesn't want
to make.

-- lrb
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News